Alzamend Neuro, Inc. (ALZN)
|Net Income (ttm)||-8.30M|
|Day's Range||1.49 - 1.69|
|52-Week Range||1.49 - 33.55|
|Price Target||11.63 (+665.1%)|
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida. [Read more...]
Financial PerformanceFinancial Statements
According to 2 analysts, the average rating for Alzamend Neuro stock is "Strong Buy." The 12-month stock price forecast is 11.63, which is an increase of 665.13% from the latest price.
Can penny stocks continue to show momentum next year? The post Here's 3 Top Penny Stocks For Your January Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate
Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determine ...
The company hopes to advance the standard of care for people with dementia.
5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News an...
ALZN stock has been on the move higher in anticipation that Alzamend Neuro will soon share the results from one of its key medication studies. The post ALZN Stock Alert: What Is Going on With Alzamend N...
5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Check these penny stocks out for your watchlist this week The post Are These Penny Stocks on Your Watchlist This Week? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Which biotech penny stocks are you watching this month? The post Best Biotech Penny Stocks to Buy in November?
Today, investors in preclinical biotech company Alzamend Neuro and ALZN stock are seeing impressive gains of more than 25% currently. The post ALZN Stock: Why Is Little-Known Alzamend Neuro Gaining Today?
Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path f...
Alzamend Neuro (ALZN) stock is on the move Thursday after getting an update from the U.S. Food and Drug Administration (FDA). The post ALZN Stock: The Alzheimer's Clinical Trial News That Has Alzamend N...
Alzamend Neuro Inc (NASDAQ: ALZN) is surging higher Thursday after the company announced it received a written response to its meeting request relating to its Type B Pre‑IND application from the FDA pro...
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to ...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #2nd_Treatment_to_Clinic--Alzamend Neuro Gets Positive FDA Pre-IND Response for AL002, a Therapeutic Vaccine that Seeks to Restore Patient's Immuno System to Comba...
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzhei...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Initiates Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease; Doses First Participant Group
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia ...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Additional $2M Investment from Digital Power Lending Due to Its IND Application for AL001 for Dementia Related to Alzheimers
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the A...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits Pre-IND for AL002 as Therapeutic Vaccine That Seeks to Restore Ability of Patient's Immunological System to Combat Alzheimer's
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug ...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives FDA “Study May Proceed” Letter for AL001 Phase 1 Clinical Study Investigational New Drug Application for Alzheimer's Disease
Investors have been driving it lower for over a month now, but the stock just reached a curious price level.
There's never been a better time to be a mouse with Alzheimer's disease.
Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models
Alzamend Neuro Inc (NASDAQ: ALZN) has announced positive toxicology results for AL002 in a toxicology study using a transgenic mouse model of Alzheimer's disease. Charles River Laboratories conducted t...
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzhei...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Positive Results for AL002, a Mutant-Peptide Vaccine, in GLP CRL Tox Study Using Alzheimer's Disease Transgenic Mouse Model
TAMPA, Fla.--(BUSINESS WIRE)---- $ALZN #505b2--Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today at 9:15am ET; Alzamend Celebrates Successful Initial Public Offering and Corporate Milestone
Ault Global Holdings Inc (NYSE: DPW), a diversified holding company, has announced that Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug application to the FDA for a Phase 1 s...
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits IND Application to the FDA for AL001, a lithium-based ionic cocrystal oral therapy for Dementia Related to Alzheimer's Disease